Targeting a Targeted Drug: An Approach Toward Hypoxia-Activatable Tyrosine Kinase Inhibitor Prodrugs

Tyrosine kinase inhibitors (TKIs), which have revolutionized cancer therapy over the past 15 years, are limited in their clinical application due to serious side effects. Therefore, we converted two approved TKIs (sunitinib and erlotinib) into 2-nitroimidazole-based hypoxia-activatable prodrugs. Kin...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:ChemMedChem
Hlavní autoři: Karnthaler-Benbakka, Claudia, Groza, Diana, Koblmüller, Bettina, Terenzi, Alessio, Holste, Katharina, Haider, Melanie, Baier, Dina, Berger, Walter, Heffeter, Petra, Kowol, Christian R., Keppler, Bernhard K.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2016
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6151264/
https://ncbi.nlm.nih.gov/pubmed/27706901
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cmdc.201600417
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky